Retatrutide vs Survodutide
Research Verdict
Retatrutide is the stronger research reference for the stated comparison criteria. Retatrutide is the stronger research reference for obesity magnitude because its Phase 3 topline weight-loss signal is substantially larger; choose survodutide when liver/MASH biology is the central question.
Quick Answers
Which is better, Retatrutide or Survodutide?
Retatrutide is the stronger research reference for the stated comparison criteria. Retatrutide is the stronger research reference for obesity magnitude because its Phase 3 topline weight-loss signal is substantially larger; choose survodutide when liver/MASH biology is the central question.
What is the key difference between Retatrutide and Survodutide?
Retatrutide adds GIP receptor agonism on top of survodutide's GLP-1/glucagon mechanism - the question is whether the triple mechanism's additional weight loss justifies any incremental complexity or risk.
Evidence Comparison
Retatrutide: Lilly has reported five positive Phase 3 studies, including -28.3% at 80 weeks in TRIUMPH-1 and -20.8% to -22.6% in later high-risk populations. Survodutide: published SYNCHRONIZE-1 treatment-regimen estimates were -12.2% and -13.0% at 76 weeks versus -5.4% placebo; the sponsor's 16.6% figure uses a different efficacy estimand. Both remain investigational.
Evidence Context Favoring Retatrutide
Research investigating maximum multi-agonist weight loss where the triple mechanism and 24.2% Phase 2 signal are of interest.
Evidence Context Favoring Survodutide
Research focused on GLP-1/glucagon dual agonism specifically, or NASH/liver fat reduction where glucagon receptor activation may have particular hepatic benefits.
Side-by-Side Snapshot
| Evidence grade | Retatrutide: Level B Survodutide: Level B |
|---|---|
| Research status | Retatrutide: Phase 3 Survodutide: Phase 3 |
| Primary category | Retatrutide: Weight Loss & Metabolic Survodutide: Weight Loss & Metabolic |
| Cited studies | Retatrutide: 5 Survodutide: 4 |